Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Cogent Biosciences (COGT) Return on Capital Employed (2018 - 2026)

Cogent Biosciences' Return on Capital Employed history spans 9 years, with the latest figure at 41.98% for Q1 2026.

  • Quarterly Return on Capital Employed rose 7047.0% to 41.98% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 41.98% through Mar 2026, up 7047.0% year-over-year, with the annual reading at 58.61% for FY2025, 4554.0% up from the prior year.
  • Return on Capital Employed came in at 41.98% for Q1 2026, up from 53.96% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 39.89% in Q3 2022 to a low of 135.66% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 59.22% (2024), against an average of 68.55%.
  • Year-over-year, Return on Capital Employed plummeted -7644bps in 2025 and then soared 7047bps in 2026.
  • Cogent Biosciences' Return on Capital Employed stood at 51.1% in 2022, then plummeted by -37bps to 70.25% in 2023, then tumbled by -31bps to 91.9% in 2024, then skyrocketed by 41bps to 53.96% in 2025, then rose by 22bps to 41.98% in 2026.
  • Per Business Quant, the three most recent readings for COGT's Return on Capital Employed are 41.98% (Q1 2026), 53.96% (Q4 2025), and 106.76% (Q3 2025).